238 related articles for article (PubMed ID: 25317566)
1. DFG-out mode of inhibition by an irreversible type-1 inhibitor capable of overcoming gate-keeper mutations in FGF receptors.
Huang Z; Tan L; Wang H; Liu Y; Blais S; Deng J; Neubert TA; Gray NS; Li X; Mohammadi M
ACS Chem Biol; 2015 Jan; 10(1):299-309. PubMed ID: 25317566
[TBL] [Abstract][Full Text] [Related]
2. Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors.
Tan L; Wang J; Tanizaki J; Huang Z; Aref AR; Rusan M; Zhu SJ; Zhang Y; Ercan D; Liao RG; Capelletti M; Zhou W; Hur W; Kim N; Sim T; Gaudet S; Barbie DA; Yeh JR; Yun CH; Hammerman PS; Mohammadi M; Jänne PA; Gray NS
Proc Natl Acad Sci U S A; 2014 Nov; 111(45):E4869-77. PubMed ID: 25349422
[TBL] [Abstract][Full Text] [Related]
3. Molecular mechanisms of the anti-cancer drug, LY2874455, in overcoming the FGFR4 mutation-based resistance.
Dehghanian F; Alavi S
Sci Rep; 2021 Aug; 11(1):16593. PubMed ID: 34400727
[TBL] [Abstract][Full Text] [Related]
4. Insight into ponatinib resistance mechanisms in rhabdomyosarcoma caused by the mutations in FGFR4 tyrosine kinase using molecular modeling strategies.
Wu C; Chen X; Chen D; Xia Q; Liu Z; Li F; Yan Y; Cai Y
Int J Biol Macromol; 2019 Aug; 135():294-302. PubMed ID: 31128178
[TBL] [Abstract][Full Text] [Related]
5. Targeting wild-type and mutationally activated FGFR4 in rhabdomyosarcoma with the inhibitor ponatinib (AP24534).
Li SQ; Cheuk AT; Shern JF; Song YK; Hurd L; Liao H; Wei JS; Khan J
PLoS One; 2013; 8(10):e76551. PubMed ID: 24124571
[TBL] [Abstract][Full Text] [Related]
6. Characterization of FGF401 as a reversible covalent inhibitor of fibroblast growth factor receptor 4.
Zhou Z; Chen X; Fu Y; Zhang Y; Dai S; Li J; Chen L; Xu G; Chen Z; Chen Y
Chem Commun (Camb); 2019 May; 55(42):5890-5893. PubMed ID: 31041948
[TBL] [Abstract][Full Text] [Related]
7. Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance.
Zhou T; Commodore L; Huang WS; Wang Y; Thomas M; Keats J; Xu Q; Rivera VM; Shakespeare WC; Clackson T; Dalgarno DC; Zhu X
Chem Biol Drug Des; 2011 Jan; 77(1):1-11. PubMed ID: 21118377
[TBL] [Abstract][Full Text] [Related]
8. A structure-guided approach to creating covalent FGFR inhibitors.
Zhou W; Hur W; McDermott U; Dutt A; Xian W; Ficarro SB; Zhang J; Sharma SV; Brugge J; Meyerson M; Settleman J; Gray NS
Chem Biol; 2010 Mar; 17(3):285-95. PubMed ID: 20338520
[TBL] [Abstract][Full Text] [Related]
9. Structural analysis of DFG-in and DFG-out dual Src-Abl inhibitors sharing a common vinyl purine template.
Zhou T; Commodore L; Huang WS; Wang Y; Sawyer TK; Shakespeare WC; Clackson T; Zhu X; Dalgarno DC
Chem Biol Drug Des; 2010 Jan; 75(1):18-28. PubMed ID: 19895503
[TBL] [Abstract][Full Text] [Related]
10. The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder.
Roskoski R
Pharmacol Res; 2020 Jan; 151():104567. PubMed ID: 31770593
[TBL] [Abstract][Full Text] [Related]
11. Molecular mechanism of D816X mutation-induced c-Kit activation and -mediated inhibitor resistance in gastrointestinal stromal tumor.
Jiang H; Shao W; Wang Y; Xu R; Zhou L; Mu X
J Mol Graph Model; 2018 Sep; 84():189-196. PubMed ID: 30015051
[TBL] [Abstract][Full Text] [Related]
12. The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.
Byron SA; Chen H; Wortmann A; Loch D; Gartside MG; Dehkhoda F; Blais SP; Neubert TA; Mohammadi M; Pollock PM
Neoplasia; 2013 Aug; 15(8):975-88. PubMed ID: 23908597
[TBL] [Abstract][Full Text] [Related]
13. Conformational analysis of the DFG-out kinase motif and biochemical profiling of structurally validated type II inhibitors.
Vijayan RS; He P; Modi V; Duong-Ly KC; Ma H; Peterson JR; Dunbrack RL; Levy RM
J Med Chem; 2015 Jan; 58(1):466-79. PubMed ID: 25478866
[TBL] [Abstract][Full Text] [Related]
14. Crystal Structure of the FGFR4/LY2874455 Complex Reveals Insights into the Pan-FGFR Selectivity of LY2874455.
Wu D; Guo M; Philips MA; Qu L; Jiang L; Li J; Chen X; Chen Z; Chen L; Chen Y
PLoS One; 2016; 11(9):e0162491. PubMed ID: 27618313
[TBL] [Abstract][Full Text] [Related]
15. Quantitative conformational profiling of kinase inhibitors reveals origins of selectivity for Aurora kinase activation states.
Lake EW; Muretta JM; Thompson AR; Rasmussen DM; Majumdar A; Faber EB; Ruff EF; Thomas DD; Levinson NM
Proc Natl Acad Sci U S A; 2018 Dec; 115(51):E11894-E11903. PubMed ID: 30518564
[TBL] [Abstract][Full Text] [Related]
16. Structural mechanisms determining inhibition of the collagen receptor DDR1 by selective and multi-targeted type II kinase inhibitors.
Canning P; Tan L; Chu K; Lee SW; Gray NS; Bullock AN
J Mol Biol; 2014 Jun; 426(13):2457-70. PubMed ID: 24768818
[TBL] [Abstract][Full Text] [Related]
17. Structural insights into FGFR kinase isoform selectivity: diverse binding modes of AZD4547 and ponatinib in complex with FGFR1 and FGFR4.
Tucker JA; Klein T; Breed J; Breeze AL; Overman R; Phillips C; Norman RA
Structure; 2014 Dec; 22(12):1764-1774. PubMed ID: 25465127
[TBL] [Abstract][Full Text] [Related]
18. Ponatinib overcomes FGF2-mediated resistance in CML patients without kinase domain mutations.
Traer E; Javidi-Sharifi N; Agarwal A; Dunlap J; English I; Martinez J; Tyner JW; Wong M; Druker BJ
Blood; 2014 Mar; 123(10):1516-24. PubMed ID: 24408322
[TBL] [Abstract][Full Text] [Related]
19. Structural analysis of the human fibroblast growth factor receptor 4 kinase.
Lesca E; Lammens A; Huber R; Augustin M
J Mol Biol; 2014 Nov; 426(22):3744-3756. PubMed ID: 25219510
[TBL] [Abstract][Full Text] [Related]
20. First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway.
Hagel M; Miduturu C; Sheets M; Rubin N; Weng W; Stransky N; Bifulco N; Kim JL; Hodous B; Brooijmans N; Shutes A; Winter C; Lengauer C; Kohl NE; Guzi T
Cancer Discov; 2015 Apr; 5(4):424-37. PubMed ID: 25776529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]